AARDVARK THERAPEUTICS INC (AARD) Stock News

USA - Nasdaq - NASDAQ:AARD - US0029421007 - Common Stock

9.67 USD

+0.3 (+3.2%)

Last: 11/26/2025, 8:14:15 PM

9.67 USD

0 (0%)

After Hours: 11/26/2025, 8:14:15 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

AARD Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics to Present at Upcoming Investor Conferences in December

14 days ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates

14 days ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates

16 days ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

4 months ago - By: The Motley Fool

Aardvark Therapeutics Reports Q2 Loss

16 days ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

20 days ago - By: Benzinga - Mentions: PI FHTX

This Aardvark Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday

23 days ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025

23 days ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025

24 days ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

24 days ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

24 days ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics to Present at Upcoming Investor Conferences in November

a month ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek

2 months ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome

2 months ago - By: Benzinga - Mentions: BLDR COIN POOL WYFI

This Coinbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

2 months ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum

2 months ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum

3 months ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

3 months ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics to Present at Upcoming Investor Conferences in September

3 months ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics to Present at Upcoming Investor Conferences in September

4 months ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates

4 months ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates

4 months ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy

4 months ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy

4 months ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

4 months ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

5 months ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference

5 months ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference

6 months ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions

6 months ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions

7 months ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

7 months ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

7 months ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics to Present at Upcoming Investor Conferences in May

7 months ago - By: Aardvark Therapeutics, Inc.

Aardvark Therapeutics to Present at Upcoming Investor Conferences in May